Uncategorized
EU Regulators Confirm No Link Between GLP-1 Drugs and Suicidal Thoughts
GLP-1 drugs, Ozempic, Wegovy, European Medicines Agency (EMA), No link to suicidal thoughts, Investigation
Enlivex Stock Plunges 50% Following Mixed Phase II Sepsis Results for Allocetra Cell Therapy
Enlivex Therapeutics, Allocetra Cell Therapy, Phase II Study, Sepsis Treatment, Stock Plummet, Mixed Results, Septic Shock, Urinary Tract Infection (UTI)
AstraZeneca’s FASENRA Gains FDA Approval for Add-On Maintenance Treatment of Severe Asthma in Children Aged 6-11
AstraZeneca, FASENRA, Benralizumab, Severe Asthma, Pediatric Label Expansion, FDA Approval, Children Aged 6-11
Adaptimmune Terminates $3 Billion Collaboration with Roche’s Genentech for Off-the-Shelf T Cell Therapies
Adaptimmune, Roche, Genentech, Off-the-shelf T cell therapies, $3 billion biobucks pact, Collaboration termination
Eli Lilly’s State Law Attempt to Halt Florida Compounding Pharmacy’s Tirzepatide Sales Dismissed
Eli Lilly, Florida compounding pharmacy, RXCompoundStore.com, Tirzepatide (Mounjaro/ Zepbound), Judge Roy Altman, Federal Food/ Drug/ and Cosmetic Act (FDCA), Frivolous lawsuits
Record-Breaking 323 Medications in Active Shortage in US, ASHP Reports
Drug shortages, US, Record-high, American Society of Health-System Pharmacists (ASHP), 323 medications, Active shortages, Generic sterile injectable medications, Cancer chemotherapy drugs, ADHD medications, Adderall, Drug Enforcement Administration (DEA), Drug supply chains, Policy recommendations
Amylyx Reveals Interim Rare Disease Data for Withdrawn ALS Therapy
Amylyx, Rare disease data, ALS drug withdrawal, Interim results, Rare neurological disorder
Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Boost Immunology Trail
Vertex Pharmaceuticals, Alpine Immune Sciences, $4.9 billion acquisition, Immunology trail
US Drug Shortages Hit Record High Since 2001: ASHP Report
Drug shortages, Record high, American Society of Health-System Pharmacists (ASHP), 323 drugs in shortage, Chemotherapy drugs, ADHD therapies, Central nervous system stimulants, Antimicrobials, Hormone agents, Intravenous fluids, Drug Enforcement Administration (DEA), Biden administration, White House Council on Supply Chain Resilience, Defense Production Act (DPA), Incentives for hospitals, Quality concerns, Controlled substances
Novartis Secures $1B Protein Degrader Deal with Arvinas and Initiates MorphoSys Tender Offer
Novartis, Arvinas, Protein Degrader Deal, PROTAC® Androgen Receptor Degrader, MorphoSys Tender Offer